Combination Therapy with Pioglitazone and SGLT2 Inhibitors

Introduction to Combination Therapy

The American Diabetes Association recommends the combination of pioglitazone and SGLT2 inhibitors, such as empagliflozin, for the treatment of type 2 diabetes, as it may offer complementary cardiovascular benefits while mitigating fluid retention risks associated with pioglitazone 1, 2

The American College of Cardiology suggests that pioglitazone is contraindicated in all patients with established heart failure, regardless of NYHA functional class, due to the risk of fluid retention and heart failure events 3, 4, 5
The combination of pioglitazone and SGLT2 inhibitors should be used with extreme caution in patients at high cardiovascular risk without established heart failure, as the SGLT2 inhibitor component provides some protection against heart failure development, but does not eliminate pioglitazone's risk 3

For patients with metabolic dysfunction-associated steatohepatitis (MASH) or high-risk liver fibrosis, the combination of pioglitazone and an SGLT2 inhibitor addresses both liver disease and cardiovascular risk, with pioglitazone improving steatohepatitis resolution 2, 7
In patients with type 2 diabetes and chronic kidney disease, SGLT2 inhibitors provide cardiorenal benefits independent of glucose lowering, and can be used down to eGFR <20 mL/min/1.73 m², while pioglitazone can be continued for glycemic control 1

The American Journal of Kidney Diseases recommends using lower pioglitazone doses (15 or 30 mg/day) rather than maximum doses to minimize fluid retention, weight gain, and fracture risk, with the SGLT2 inhibitor's diuretic effect allowing for safer pioglitazone use at these lower doses 1
When adding either drug to existing therapy, the Journal of the American College of Cardiology suggests reducing sulfonylurea dose by 50% or discontinuing if already on minimal dose, and reducing total daily insulin dose by 20% when initiating SGLT2 inhibitor therapy 6, 9

The American College of Cardiology recommends monitoring weight and edema assessment at each visit, particularly in the first 3 months, as well as signs/symptoms of heart failure, ketone monitoring if symptoms develop, genital mycotic infection surveillance, and bone health and fracture risk assessment 4, 5, 6
The Metabolism: Clinical and Experimental journal suggests monitoring renal function (eGFR) every 3-6 months to guide SGLT2 inhibitor continuation, liver enzymes if using for MASH or if symptoms suggest hepatotoxicity, and lipid panel to assess pioglitazone's beneficial effects on HDL and triglycerides 1, 7